Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is associated with increased excitatory activity within the subthalamic nucleus (STN). We sought to inhibit STN output in hemiparkinsonian macaques by transfection with adeno-associated virus (AAV) containing the gene for glutamic acid decarboxylase (GAD). In total, 13 macaques were rendered hemiparkinsonian by right intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injection. Seven animals were injected with AAV-GAD into the right STN, and six received an AAV gene for green fluorescent protein (GFP). Videotaped motor ratings were performed in a masked fashion on a weekly basis over a 55-week period. At 56 weeks, the animals were scanned with 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET). Histological examination was performed at the end of the study. No adverse events were observed after STN gene therapy. We found that the clinical rating scores for the two treatment groups had different patterns of change over time (group × time interaction, P<0.001). On FDG PET, the GAD animals exhibited an increase in glucose utilization in the right motor cortex relative to GFP controls ( P<0.001). Metabolism in this region correlated with clinical ratings at end point ( P<0.01). Histology confirmed GAD expression in treated animals. These findings suggest that STN AAV-GAD is well tolerated and potentially effective in a primate model of PD. The changes in motor cortical glucose utilization observed after gene therapy are consistent with the modulation of metabolic brain networks associated with this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic topography of parkinsonism
Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S., et al. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.99 · Cited by 455 · cited 1×
“By contrast, the present findings of pallidal and cerebellar hypermetabolism subsequent to MPTP are consistent with FDG PET findings in PD patients (Eidelberg et al, 1994; Moeller et al, 1999).”
ResultSelf-citationThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 1×
“The time course of the GAD CRS curve with a progressive improvement over several weeks is consistent with the delay in reaching peak expression found with AAV-mediated gene transfer (Herzog et al, 1997; Thomas et al, 2004).”
ResultSubthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model
Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L., & During, M. J. (2002) · Science · doi:10.1126/science.1074549 · Cited by 325 · cited 1×
“Based on this, we reported behavioral improvement after the delivery of AAV-GAD into the STN of a standard rodent model of PD (Luo et al, 2002).”
BackgroundSelf-citationStefurak, T., Mikulis, D., Mayberg, H., Lang, A. E., Hevenor, S., Pahapill, P., Saint‐Cyr, J., & Lozano, A. (2003) · Movement Disorders · doi:10.1002/mds.10593 · Cited by 215 · cited 1×
“This is consistent with previous findings of increased motor cortical activity in PD patients undergoing a variety of stereotaxic procedures for advanced symptoms (Eidelberg et al, 1996; Stefurak et al, 2003; Sestini et al, 2005).”
Result
Cited by
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Self-citationLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationChanges in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
Self-citationEmerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Metadata
- Authors
- Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C., Moirano, J., Fitzsimons, H., Roitberg, B. Z., Tuccar, E., Roberts, A., Kaplitt, M. G., & Eidelberg, D.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2007-03
- Volume
- 27
- Issue
- 3
- Pages
- 501-509
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2030318177
- Cited by
- 134
- References
- 4
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism. https://app.cochat.ai/papers/10.1038/sj.jcbfm.9600364
- The paper
- Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C., Moirano, J., Fitzsimons, H., Roitberg, B. Z., Tuccar, E., Roberts, A., Kaplitt, M. G., & Eidelberg, D. (2007). Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1038/sj.jcbfm.9600364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.